Talquetamab,dexamethasone,elranatamab,Teclistamab,Daratumumab,Pomalidomide,Lenalidomide,Bortezomib,Nirogacestat,Idecabtagene vicleucel,mezigdomide,Alnuctamab,BMS-986393,BMS-986354,cevostamab,modakafusp alfa
Janssen,pfizer,Genmab,springworks therapeutics,Takeda,bms,roche,2seventy bio
['majestec,(-majestec-1),(-majestec1),(-majestec 1),(-majestec-3),(-majestec3),(-majestec 3),(-majestec-i),(-majestec i),(-majesteci)', 'mezigdomide', 'alnuctamab', 'karmma2', 'modakafusp', 'cevostamab', 'bms986354', 'elrana ', 'karmma', 'bms-986393', 'thanks', 'majestec2', 'monumental1', 'bms']
my abstract selection posted sometime before #ash22 is still valid after listening to these abstracts! thanks to all speakers and contributors for pushing the field forward! 
Professor and head of Hematology Sorbonne Univ.; past-president of the EBMT; Chairman of the IACH; Editor in Chief: Bone Marrow Transplant; Clin Hematol Int.